Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - clopidogrelum - lactab - clopidogrelum 75 mg à clopidogreli hydrochloridum, macrogolum 6000, cellulosum microcristallinum, crospovidonum, de la silice colloidalis anhydrica, huile de ricin hydrogenatum, Überzug: poly(alcool vinylicus), macrogolum 3000, talc, e 171, e 172, pour compresso de la brume. - inhibiteur de l'agrégation plaquettaire - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

axapharm ag - clopidogrelum - comprimés pelliculés - clopidogrelum 75 mg à clopidogreli besilas, macrogolum 6000, cellulosum microcristallinum, crospovidonum, huile de ricin hydrogenatum, Überzug: ethylcellulosum, macrogolum 6000, e 171, pour compresso de la brume. - inhibiteur de l'agrégation plaquettaire - synthetika

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz sa-nv - chlorhydrate de clopidogrel 83,48 mg - eq. clopidogrel 75 mg - comprimé pelliculé - 75 mg - chlorhydrate de clopidogrel 83.48 mg - clopidogrel

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - hydrogénosulfate de clopidogrel 97,857 mg - eq. clopidogrel 75 mg - comprimé pelliculé - 75 mg - hydrogénosulfate de clopidogrel 97.857 mg - clopidogrel

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - bésilate de clopidogrel 111,86 mg - eq. clopidogrel 75 mg - comprimé pelliculé - 75 mg - bésilate de clopidogrel - clopidogrel

Union européenne - français - EMA (European Medicines Agency)

sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - agents antithrombotiques - coronarien aigu syndromemyocardial du myocarde.

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

billev pharma aps - clopidogrel - comprimé - 75 mg - composition pour un comprimé > clopidogrel : 75 mg . sous forme de : hydrogénosulfate de clopidogrel > acide acétylsalicylique : 75 mg - inhibiteurs de l’agrégation plaquettaire à l’exclusion de l’héparine

France - français - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

billev pharma aps - clopidogrel - comprimé - 75 mg - composition pour un comprimé > clopidogrel : 75 mg . sous forme de : hydrogénosulfate de clopidogrel > acide acétylsalicylique : 100 mg - inhibiteurs de l’agrégation plaquettaire à l’exclusion de l’héparine

Union européenne - français - EMA (European Medicines Agency)

viatris limited - bésilate de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agents antithrombotiques - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). Élévation du segment st infarctus aigu du myocarde, en association avec de l'aas dans traitée médicalement les patients éligibles à un traitement thrombolytique. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pour de plus amples informations, veuillez vous reporter à la section 5.

Union européenne - français - EMA (European Medicines Agency)

taw pharma (ireland) limited - chlorhydrate de clopidogrel - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agents antithrombotiques - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.